Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “IPSS Risk Category Intermediate-2”

31 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 31 results

Testing effectiveness (Phase 2)UnknownNCT00885508
What this trial is testing

The Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5q

Who this might be right for
Myelodysplastic SyndromeChronic Myelomonocytic LeukemiaAcute Myeloid Leukemia
Groupe Francophone des Myelodysplasies 85
Testing effectiveness (Phase 2)UnknownNCT00022321
What this trial is testing

Gemtuzumab in Treating Patients With Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndromes
Jonsson Comprehensive Cancer Center
Not applicableStudy completedNCT05218902
What this trial is testing

Azacitidine in Participants With International Prognostic Scoring System (IPSS) Intermediate-2 and High-risk Myelodysplastic Syndromes (MDS), or Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)

Who this might be right for
Myelodysplastic SyndromesLeukemia, Myelomonocytic, ChronicLeukemia, Myeloid, Acute
Bristol-Myers Squibb 290
Testing effectiveness (Phase 2)Ended earlyNCT02152956
What this trial is testing

Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)

Who this might be right for
AML
MacroGenics 244
Testing effectiveness (Phase 2)Ended earlyNCT02010645
What this trial is testing

Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS)

Who this might be right for
Leukemia
M.D. Anderson Cancer Center 6
Testing effectiveness (Phase 2)Study completedNCT01873703
What this trial is testing

Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndrome
Helsinn Healthcare SA 102
Testing effectiveness (Phase 2)Study completedNCT02016781
What this trial is testing

Allo vs Hypomethylating/Best Supportive Care in MDS (BMTCTN1102)

Who this might be right for
MDS
Medical College of Wisconsin 384
Testing effectiveness (Phase 2)WithdrawnNCT00867061
What this trial is testing

Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS)

Who this might be right for
Myelodysplastic Syndrome
Traws Pharma, Inc.
Testing effectiveness (Phase 2)Study completedNCT01692366
What this trial is testing

Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly

Who this might be right for
Myelofibrosis
Bristol-Myers Squibb 8
Testing effectiveness (Phase 2)Study completedNCT00906334
What this trial is testing

Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk

Who this might be right for
Myelodysplastic Syndrome
Traws Pharma, Inc. 14
Testing effectiveness (Phase 2)Study completedNCT01088373
What this trial is testing

Lenalidomide Combined to Azacitidine in Intermediate-2 or High Risk MDS With Del 5q

Who this might be right for
Myelodysplastic Syndromes
Groupe Francophone des Myelodysplasies 50
Testing effectiveness (Phase 2)Study completedNCT03047993
What this trial is testing

Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome

Who this might be right for
Acute Myeloid Leukemia With Multilineage DysplasiaBlasts 20-30 Percent of Bone Marrow Nucleated CellsBlasts 20-30 Percent of Peripheral Blood White Cells+4 more
M.D. Anderson Cancer Center 28
Testing effectiveness (Phase 2)Not Yet RecruitingNCT02944955
What this trial is testing

BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Who this might be right for
Myelodysplastic Syndrome (MDS)
BioLite, Inc. 52
Testing effectiveness (Phase 2)Study completedNCT00451048
What this trial is testing

Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Who this might be right for
Chronic Myelomonocytic Leukemiade Novo Myelodysplastic SyndromesMyelodysplastic Syndromes+1 more
National Cancer Institute (NCI) 10
Testing effectiveness (Phase 2)Study completedNCT01305460
What this trial is testing

Intensified Azacitidine in High Risk Myelodysplastic Syndrome (MDS)

Who this might be right for
Myelodysplastic Syndrome
Groupe Francophone des Myelodysplasies 27
Large-scale testing (Phase 3)Study completedNCT01437787
What this trial is testing

Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis

Who this might be right for
Hematopoietic Neoplasm
Bristol-Myers Squibb 289
Testing effectiveness (Phase 2)Ended earlyNCT00666497
What this trial is testing

Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Who this might be right for
Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)
Mirati Therapeutics Inc. 6
Not applicableStudy completedNCT00987584
What this trial is testing

Phase II Cont. IV of ON 01910.Na in MDS w/ Trisomy 8/Intermed-1, 2/High Risk

Who this might be right for
Myelodysplastic Syndromes
Peter L Greenberg 13
Large-scale testing (Phase 3)Study completedNCT04617028
What this trial is testing

Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis

Who this might be right for
Myelofibrosis
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 105
Testing effectiveness (Phase 2)UnknownNCT00424229
What this trial is testing

Lenalidomide in Subjects With intermediate2 or High MDS Associated With a Deletion (DEL) 5q [31]

Who this might be right for
Myelodysplastic Syndromes
Groupe Francophone des Myelodysplasies 49
Load More Results